- Home
- SKIN vs INBX Comparison
SKIN vs INBX Comparison
Compare SKIN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- INBX
- Stock Information
- Founded
- SKIN 1997
- INBX 2010
- Country
- SKIN United States
- INBX United States
- Employees
- SKIN N/A
- INBX N/A
- Industry
- SKIN Package Goods/Cosmetics
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SKIN Consumer Discretionary
- INBX Health Care
- Exchange
- SKIN Nasdaq
- INBX Nasdaq
- Market Cap
- SKIN 295.5M
- INBX 345.8M
- IPO Year
- SKIN N/A
- INBX 2020
- Fundamental
- Price
- SKIN $2.53
- INBX $27.52
- Analyst Decision
- SKIN Hold
- INBX Hold
- Analyst Count
- SKIN 1
- INBX 2
- Target Price
- SKIN $1.25
- INBX N/A
- AVG Volume (30 Days)
- SKIN 895.2K
- INBX 113.1K
- Earning Date
- SKIN 11-11-2025
- INBX 11-13-2025
- Dividend Yield
- SKIN N/A
- INBX N/A
- EPS Growth
- SKIN N/A
- INBX N/A
- EPS
- SKIN N/A
- INBX N/A
- Revenue
- SKIN $310,064,000.00
- INBX $1,400,000.00
- Revenue This Year
- SKIN N/A
- INBX N/A
- Revenue Next Year
- SKIN $6.05
- INBX N/A
- P/E Ratio
- SKIN N/A
- INBX N/A
- Revenue Growth
- SKIN N/A
- INBX N/A
- 52 Week Low
- SKIN $0.78
- INBX $10.81
- 52 Week High
- SKIN $2.56
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- SKIN 67.00
- INBX 58.56
- Support Level
- SKIN $2.22
- INBX $27.51
- Resistance Level
- SKIN $2.51
- INBX $30.23
- Average True Range (ATR)
- SKIN 0.15
- INBX 1.47
- MACD
- SKIN 0.04
- INBX -0.09
- Stochastic Oscillator
- SKIN 95.16
- INBX 54.53
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.